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SI/CTR Abstract 
In vivo T cell genetic engineering with melanoma-specific TCR and CAR 
 
Toby Mathew, Vitali Alexeev* 
Introduction: Adoptive cell transfer (ACT) using T cells genetically engineered to 
express tumor-specific T cell receptors (TCR) and Chimeric Antigen receptors (CAR) 
have demonstrated high remission rates in patients with advanced cancers. Targeting of 
metastatic melanoma with TCR-modified recombinant T cells showed clinically 
significant response in the majority of patients. However, due to certain drawbacks, this 
powerful strategy is not yet available for broad clinical application. We propose that in 
vivo genetic engineering approach may allow overcoming several drawbacks 
associated ACT and could convert it into generic and cost-effective modality to bring 
recombinant T cell therapies to general patient population.  
Methods: Specifically, we suggested intradermal delivery of the recombinant TCR and 
CAR encoding plasmids into T cells combined with ΦC31 integrase-mediated gene 
transfer could be used to generate functional melanoma-specific T cells directly in 
tumor-bearing subjects. After injecting mice through in vivo electroporation, we observe 
the recruitment of T cells and plasmid incorporation. 
Results: We obtained solid preliminary data showing that T cells genetically engineered 
to express tyrosinase-specific TCR in vivo can eliminate malignant lesions and produce 
tumor-specific immunologic memory through analysis of splenocytes. We also showed 
that this approach could be developed to generate CAR-expressing T cells to target 
malignant lesions. 
Discussion: Our results support that In vivo T cell genetic engineering with melanoma 
specific TCR can have a significant effect on recruiting T cells and diminishing and 
eliminating melanoma. This method could have significant improvements on reducing 
on-and-off target toxicities and costs but further studies must be done for future efficacy.  
